FDA Considers New Regulatory Pathways For Some Cellular Products
Executive Summary
The US agency is re-evaluating its criteria for certain human cells, tissues and cellular and tissue-based products (HCT/Ps) that are not ideally regulated as BLAs. A 2014 guidance on cord blood products could serve a template, industry suggests.
You may also be interested in...
MDUFA V Passed By US House Health Subcommittee
The user fee package was among several health-related bills that the subcommittee took up on Wednesday.
FDA Aims To Clarify Human Cell/Tissue Regulation With Upcoming Meeting, Guidance Documents
FDA announced an April hearing to discuss four open draft guidance documents clarifying the regulation of human cells, tissues, or cellular or tissue-based products.
Drug Promotion: Growth In Digital Marketing Warrants New Oversight Approaches, Experts Say
Panelists at a recent Duke-Margolis meeting cite growing use of native ads and patient influencers, as well as the limited attention given to presentation of risk information, in calling for a re-examination of how pharmaceutical promotion on digital platforms is regulated.